Digest Network Come funziona
Network
/
Società
Al
Non verificato

Almirall

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

10 comunicati stampa

Guarda tutti i comunicati
13/04/2026
Mercato del lavoro
Industria
Scienza
Tecnica
Associazioni/Professionisti
Biotecnologia
Salute
Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology
Fonte
Almirall
Emittente
Business Wire
1.00
0
23/03/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Psichiatria
Sanità
Eventi
Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology
Fonte
Almirall
Emittente
Business Wire
1.00
0
16/03/2026
Scienza
Giovani
Infanzia
Medicina - Varie
Famiglia
Biotecnologia
Farmaceutica
Vetrine/Shopping
Salute
Industria
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis
Fonte
Almirall
Emittente
Business Wire
1.00
0
21/03/2025
Eventi
Scienza
Biotecnologia
Farmaceutica
Sanità
Oncologia
Salute
Almirall's 16th Skin Academy Brings Together Leading Experts to Advance Skin Science and Treatment Options in Medical Dermatology
Fonte
Almirall
Emittente
Business Wire
1.00
0
14/01/2025
Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth
Fonte
Almirall
Emittente
Business Wire
1.00
0
04/12/2024
Multimedialità
Industria
Sanità
Scienza
Associazioni/Professionisti
Psichiatria
Biotecnologia
Salute
Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare
Fonte
Almirall
Emittente
Business Wire
1.00
0
25/09/2024
Multimedialità
Industria
Eventi
Biotecnologia
Farmaceutica
Finanza
Sanità
Salute
Associazioni/Professionisti
Medicina - Varie
New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis
Fonte
Almirall
Emittente
Business Wire
1.00
0
23/09/2024
Industria
Eventi
Biotecnologia
Sanità
Salute
Farmaceutica
Medicina - Varie
Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress
Fonte
Almirall
Emittente
Business Wire
1.00
0
02/07/2024
Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030
Fonte
Almirall
Emittente
Business Wire
1.00
0
28/06/2024
Fiere
Industria
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year1
Fonte
Almirall
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0